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Aims: Clinical inertia behaviour affects family physicians managing chronic disease such as diabetes. Literature
addressing clinical inertia in the management of hypoglycemia is scarce. The objectives of this study were to
create a measurement for physician clinical inertia in managing hypoglycemia (ClinInert_InHypoDM), and to
determine physicians’ characteristics associated with clinical inertia.
Methods: The study was a secondary analysis of data provided by family physicians from the InHypo-DM Study,
applying exploratory factor analysis. Principal axis factoring with an Oblimin rotation was employed to detect
underlying factors associated with physician behaviors. Multiple linear regression was used to determine asso
ciation between the ClinInert_InHypoDM scores and physician characteristics.
Results: Factor analysis identified a statistically sound 12-item one-factor scale for clinical inertia behavior. No
statistically significant differences in clinical inertia score for the studied independent variables were found.
Conclusions: This study provides a scale for assessing clinical inertia in the management of hypoglycemia. Further
testing this scale in other family physician populations will provide deeper understanding about the charac
teristics and factors that influence clinical inertia. The knowledge derived from better understanding clinical
inertia in primary care has potential to improve outcomes for patients with diabetes.

1. Introduction
Management of the patient with diabetes mellitus (DM) embodies
the spirit of primary care medicine. Because of the chronic, progressive,
and potentially disabling nature of this illness, family physicians (FP)
are often at the cornerstone of diabetes care [1]. This gate-keeping po
sition allows professionals to screen high-risk patients for diabetes,
initiate treatment, manage hyperglycemia, monitor, and fine-tune
pharmacologic therapies, as well as detect and manage microvascular
and macrovascular complications.
Evidence suggests that tight glycemic control reduces morbidity and
mortality of DM. However, the resulting risk of hypoglycemia can pre
sent a barrier to optimizing therapy and challenge patient medication
adherence [2,3].
Iatrogenic hypoglycemia is a well-known adverse event of insulin use
in people with type 1 diabetes (T1DM) but is also seen in type 2 diabetes
(T2DM) patients managed by insulin and/or secretagogues [4].
Ratzki-Leewing et al. [5] analyzed the results of one of the largest

real-world investigations of hypoglycemia epidemiology in Canada, the
InHypo-DM Study [6]. Findings from this study revealed that the inci
dence of iatrogenic hypoglycemia among adults with T2DM taking in
sulin and/or secretagogues is higher than commonly believed. While
83.0% of people with T1DM reported having experienced at least one
hypoglycemic event with an overall annualized hypoglycemia rate of
58.1 events per person-year, 62.0% of T2DM individuals experienced at
least one hypoglycemia event at a rate of 30.4 events per person-year.
The Canadian study also challenged prevailing misconceptions that se
vere hypoglycemia in T2DM is relatively infrequent [4]. Ratzki-Leewing
et al. found that among patients with DM reporting any type of hypo
glycemic event, the incidence rate of severe hypoglycemia was
approximately 37% higher in people with T2DM than that found among
those respondents with T1DM [5].
Research has identified a disconnect between the clinical goals out
lined in evidence-based guidelines for DM management and real-life
clinical practice which can be referred to as clinical inertia [7–9]. One
study identified characteristics of physicians who were most likely to

* Corresponding author at: Centre for Studies in Family Medicine, Western University, 1465 Richmond St. London, Ontario, N6G 2M1, Canada.
E-mail address: stewart.harris@schulich.uwo.ca (S.B. Harris).
https://doi.org/10.1016/j.pcd.2022.02.005
Received 15 July 2021; Received in revised form 10 February 2022; Accepted 11 February 2022
1751-9918/© 2022 The Authors. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article as: Caroline V.M. Rebicki, Primary Care Diabetes, https://doi.org/10.1016/j.pcd.2022.02.005

C.V.M. Rebicki et al.

Primary Care Diabetes xxx (xxxx) xxx

healthcare provider (HCP) questionnaire (Appendix 1). In 2016, HCPs
were recruited from two online survey panels: the professional sections
of the Canadian Diabetes Association, which consisted of 3,584 mem
bers, and an HCP panel of 5,579 members maintained by Professional
Targeted Marketing (PTM), a Canadian healthcare communications
company. Individuals were recruited via an invitation email that con
tained a Qualtrics link to the InHypo-DMHCPQ. Fig. 1 describes the
sampling method for the InHypo-DM Study. Of the invited 9,163 HCPs,
889 responded, of whom 162 were FPs.
Participants were asked to complete the 63-item InHypo-DMHCPQ in
either English or French. Data were collected on HCP’s attitudes and
clinical behaviours related to hypoglycemia management (5-point Likert
scale) as well as socio-demographics. The questionnaire was informed
by a literature review, theory-driven qualitative interviews with HCP,
and expert consultation. Questions pertaining to clinical inertia were
extracted from this dataset.

follow DM guidelines related to hyperglycemia, and therefore less in
clined to clinical inertia. These include being female, recently completed
medical training, frequently use of a computerized medical record and
working in group practice [10]. Additionally, competing demands on
the physician in the patient-physician encounter has been associated
with clinical inertia concerning hyperglycemia [11]. Another study
found that 75.5% of physicians would be more aggressive treating hy
perglycemia in their patients with diabetes if not for concerns about
hypoglycemia [12]. Clinical inertia [13] has been recognized as an
important barrier to the management of many chronic diseases,
including DM [6,14].
Despite its clinical importance, there is a paucity of literature
addressing behaviors that comprise family physician clinical inertia
concerning hypoglycemia. This study sought to redress this lack by
examining factors that make up FP clinical inertia in hypoglycemic
management. The primary objective of this study was to develop a
measure of clinical inertia specific to hypoglycemia that could be useful
as part of an education intervention, particularly for continuing medical
education. A secondary objective was to determine if there was a cor
relation between clinical inertia and FP characteristics.

2.2. Variables
Regarding the primary objective, to develop a clinical inertia scale,
we used the 13 items from the questionnaire that explored physician
attitude and behavior in managing hypoglycemia in their clinical
practice. Responses were chosen from five categories, “Never”; “Rarely”;
“Sometimes”; “Often”; and “Always”. The items of the survey and their
variable names are listed in Table 1.
Regarding the secondary objective, to assess the relationship be
tween clinical inertia and physician characteristics, the dependent var
iable was the scores from the clinical inertia score developed in the
primary objective. The independent variables used in this analysis were:
age in years; sex; years in practice; practice location; Canadian province
where the practice was located; practice type; diabetes educator desig
nation; mean number of diabetes patients seen in an average week; and
personal diagnosis of diabetes.

2. Methods
2.1. Study design, population, and data collection
The present investigation was a secondary cross-sectional analysis of
the “UnderstandINg the impact of HYPOglycemia on Diabetes Man
agement: A Survey of Perspectives and Practices” (InHypo-DM Study)
[5]. Exploratory factor analysis (EFA), employing Principal Axis Factor
(PAF) extraction with Oblimin rotation, was used to investigate the
factor structure of questionnaire items related to clinical inertia.
Conceptually, the underpinnings that guided the responses to these
items might identify a behavior pattern for clinical inertia. EFA was used
because this was an exploratory analysis with no prior theory available
to explain the phenomenon of clinical inertia [15–17]. The sample for
this study consisted of the sub-set of FPs who completed the InHypo-DM

Fig. 1. Sampling diagram.
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the factors and the scale overall. Once a final factor structure for clinical
inertia was determined, the clinical inertia score was determined by
calculating the mean value of the items in the final factor structure [16].
For the secondary objective, bivariate analyses were conducted to
determine the relationship between the clinical inertia score and the
independent variables. For continuous variables, Pearson’s correlation
was used; for dichotomous variables, t-test were used; and for categor
ical variables with more than two response categories, ANOVA was
used. Next, multiple linear regression was performed to explore the
relationship between the clinical inertia factor score and the indepen
dent variables in the model. Assumptions of normality, linearity, mul
ticollinearity, and homoscedasticity underpinning multiple linear
regression, were tested.

Table 1
InHypo-DM health care provider survey: hypoglycemia management items.
Name

Item

Effort to track progress

In general, I make an effort to keep track of my patients’
progress with regard to managing their hypoglycemia.
In general, I advise my patients to increase the frequency
of blood glucose monitoring when they are at increased
risk for hypoglycemia.
In general, I make sure that I am prepared to help my
patients manage their hypoglycemia.
In general, I am confident that I can help my patients
manage their hypoglycemia even when there is little
time.
In general, addressing the specific appointment issue
takes priority over discussing their hypoglycemia
management.
In general, helping my patients manage their
hypoglycemia is something I do routinely.
In general, helping my patients manage their
hypoglycemia is informed by current evidence and
guidelines.
In general, I take the initiative to help my patients
improve their hypoglycemia management.
In general, I explain how to manage hypoglycemia to my
patients.
In general, I discuss hypoglycemia-related guidelines
regarding driving or operating heavy machinery with my
patients.
In general, I solicit patients’ input when discussing their
hypoglycemia management.
In general, I use motivational strategies to help my
patients manage their hypoglycemia.
In general, my professional liability, according to my
specific regulatory body, directs the way I manage
patients’ hypoglycemia.

Advise to intensify
monitoring
Preparedness
Time Management
Prioritizing specific
issues
Routinely help manage
Use of guidelines
Initiative to help
improve
Explain how to manage
hypo
Discuss driving/heavy
machinery
Solicit input
Motivational strategies
Liability concerns

3. Results
There were 162 FPs who completed the questionnaire. Table 2 de
scribes the FP participants’ characteristics for the categorical variables.
The mean age of the sample was 57.5 years (SD 9.65) and respondents
had been practicing medicine for a mean of 26 years (SD 11). The
number of DM patients seen by these family physicians was, on average,
27 DM patients per week (SD 24).
Frequency for each response category on the items of the question
naire that addressed physician behavior and attitudes is presented in
Appendix 2.
One hundred and sixty respondents completed the section of the
questionnaire on behavior characteristic, with only two respondents
with missing data. The factor analysis was performed on the respondents
without missing data (N 160).
Four iterative rounds of EFA, using PAF extraction, were conducted
to find a solution. In the first round, one item loaded on its own factor
and therefore was deleted. In the second round, we ran the remaining 12
items and found a two-factor solution; however, there was no clear
clinical distinction between the two factors. In the third round, we once
again ran an EFA of the 13 items, constraining the items to a one-factor
solution. We then ran the final round which produced a 12-item scale,
and we excluded the item called “Priorities” because it had a low
loading. All remaining items loaded on the factor with values superior to
0.40. The loadings ranged from 0.437 to 0.682. This 12-item solution
explained 54% of the total variance. Table 3 shows the factor loadings
for the final round of EFA.
Given both the clinical relevance of this version and the high load
ings resulting, the items from this 12-item one-factor solution were
chosen to create the clinical inertia scale called the ClinInert_InHypoDM.

2.3. Analysis
All analyses were conducted using SPSS statistics version 25 [18]. A
descriptive analysis examined the distribution of all variables. The fre
quencies and percentages for the responses for each of the 13 potential
clinical inertia scale items were run, and missing values were identified.
For the independent variables, frequencies and percentages were run for
categorical variables and means and standard deviations were calcu
lated for continuous variables.
Exploratory Factor Analysis was used in an iterative process to
identify correlations among the 13 potential clinical inertia items that
could contribute to a clinical inertia scale. The EFA was conducted only
on cases with complete data. The first step in the EFA was to explore
assumptions of sample size, factorability of matrix and pattern of dis
tribution to determine suitability of the data set for EFA.
The suitability of the data for factor analysis was assessed by in
spection of the correlation matrix for the presence of coefficients of 0.3
and above, indicating factorability of the items. A KMO index value of
0.6 or higher and statistical significance on the Bartlett`s test of Sphe
ricity further supported the adequacy of sample size and factorability of
the correlation matrix.
The decision on how many of the extracted factors to keep was
guided by the scree plot and the Kaiser’s criterion concerning eigen
values and the total variance explained. The pattern and structure
matrices reported factor loadings for each of the 13 potential clinical
inertia items on each factor. Factor loading values in the pattern and
structure matrices equal or greater than 0.40 were considered relevant.
The achieved pattern matrix was then examined to ensure that items
loaded with significant values on each factor and to verify if each factor
was composed of items that were conceptually similar in trait. If the
produced pattern matrix did not satisfy these criteria, a new round of
EFA was run with some choices modified. This process was iterated until
a clear and clinically relevant factor solution was found.
Cronbach’s Alpha was calculated to assess the reliability of each of

Table 2
Family physician characteristics (n = 162).
Variable

Response categories

Number (%)

Sex

Male
Female
Urban
Rural
Western/Prairies
Alberta
Ontario
Quebec
Maritimes
Newfoundland & Labrador
Hospital-based
Team-based
Not team-based
Missing
Yes
No
Yes
No

91 (56.2)
71 (43.8)
122 (75.3)
40 (24.7)
17 (10.7)
12 (7.5)
87 (54.7)
13 (8.2)
12 (7.5)
18 (11.3)
8 (5.4)
63 (42.3)
69 (46.3)
9 (6.0)
9 (5.6)
153 (94.4)
14 (8.6)
148 (91.4)

Location
Province

Practice Type

Certified diabetes educator
Personal diagnosis of diabetes

Note: Western/Prairies-British Columbia, Manitoba, and Saskatchewan; Mari
time Provinces-Prince Edward Island, New Brunswick, and Nova Scotia.
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Table 3
EFA iteration 4 (Final): factor matrix.

Table 4
Multiple linear regression.

Item

Factor loading

Effort to track progress
Advise to increase monitoring
Preparedness
Time Management
Routinely help manage
Use of guidelines
Initiative to help improve
Explain how to manage hypo
Discuss driving/heavy machinery
Solicit input
Motivational strategies
Liability concerns

0.682
0.565
0.791
0.754
0.778
0.716
0.840
0.791
0.642
0.724
0.684
0.437

While sub-scales were identified statistically, there was no conceptual
clinical distinction among them.
A ClinInert_InHypoDM score was created by calculating the mean of
the response for each of the 12 items for each respondent. The mean
score for the clinical inertia score was 3.82 out of 5 with a standard
deviation of 0.611; the median was 3.83 (IQR 0.67). No reference or cutoff score values were identified for the scale. Rather, higher scores are
intended to reflect less clinical inertia because higher scores reflect more
positive and proactive behaviors described in the items.
Having established a ClinInert_InHypoDM score, the secondary
objective was met by conducting a bivariate and a multiple linear
regression analysis. There were no significant relationships found in the
bivariate analysis. In the first model, age was highly collinear with
variable years in practice, with a bivariate correlation of 0.826 (p-value
< 0.001). Therefore, age was excluded from the regression and a second
multiple linear regression analysis was performed where there was no
evidence of multicollinearity. All other assumptions of multiple linear
regression were met. There were no statistically significant relationships
between the clinical inertia score and the independent variables. Table 4
reports these results.

Model

Unstandardized
coefficients

Standard
error

95%
confidence
interval

Sig.

Constant
Years in practice

4.324
0.002

0.670
0.005

0
0.629

#DM patient/week

0.001

0.002

Sex (Reference
Male)
Location (Reference
Urban)
CDE (Reference No)

− 0.179

0.115

− 0.014

0.127

− 0.009

0.240

Personal DM
(Reference No)
Province (Reference
Ontario)
Western/Prairies

− 0.180

0.184

3.00, 5.648
− 0.008,
0.012
− 0.004,
0.005
− 0.406,
0.048
− 0.265,
0.236
− 0.482,
0.465
− 0.543,
0.184

0.217

0.175

0.217

Alberta

0.151

0.196

Quebec

0.040

0.196

Maritimes

− 0.206

0.201

Newfoundland &
Labrador
Practice Type
(Reference
Hospital)
Team-based

0.148

0.178

− 0.129,
0.563
− 0.237,
0.538
− 0.347,
0.426
− 0.605,
0.192
− 0.203,
0.499

0.013

0.146

0.929

Not team-based

0.021

0.140

− 0.276,
0.301
− 0.256,
0.298

0.749
0.121
0.911
0.971
0.33

0.443
0.84
0.307
0.406

0.881

CDE-Diabetes Educator Designation; DM-Diabetes Mellitus; Western/PrairiesBritish Columbia, Manitoba, and Saskatchewan); Maritime Provinces-Prince
Edward Island, New Brunswick, and Nova Scotia.

The major strength of this study relevant to primary care is that the
ClinInert_InHypoDM scale was developed using data from a national
sample of FPs in Canada providing diabetes care.
Limitations of this study were mostly related to its method as a
secondary analysis. The survey used in this study was based on physi
cians’ self-report of their behaviour and may not reflect actual behavior.
However, the questionnaires were anonymous and therefore likely to
elicit honest responses. Some key aspects that could measure clinical
inertia were not present in the original questionnaire, such as attitudes
and behavior of the physician in relation to patient’s results on glycemic
target or glycosylated hemoglobin levels, or questions about team-based
practice, the use of electronic medical records, telehealth and other
technology-driven clinical intelligence tools that could aid physicians in
protocols and practice guidelines.
A limitation of this study was that the questionnaire did not collect
data for the patients of the FP respondents; therefore, we were not able
to correlate FP clinical inertia scores to the hypoglycemia profile for
their patients with DM. The application of this scale will require further
study to determine reference values concerning what constitutes clinical
inertia. Future research can assess the relationship between FP scores
and clinically relevant outcomes including frequency of severe hypo
glycemia, hypoglycemia unawareness, and HbA1c concentration for the
DM patients managed by them.
While this research was designed to understand the role of physician
behaviors in clinical inertia, future studies should also investigate
physician clinical inertia behavior in comparison to their patients’
characteristics, such as non-adherence status, glycosylated hemoglobin
levels, and presence of comorbidity. The knowledge that will derive
from such a comprehensive understanding of the multi-factorial and
complex topic of clinical inertia in primary care will undoubtedly

4. Discussion
The major contribution of this study is the creation, for the first time,
of a clinical inertia scale specific to hypoglycemia management, the
ClinInert_InHypoDM scale. This practical measure will aid in under
standing and measuring this phenomenon, leading to future in
terventions that can reduce its occurrence in primary care. Clinical
inertia in the management of diabetes in primary care is a wellestablished, common, and ongoing challenge. This issue not only ap
plies to delayed intensification of therapy to optimize glycemic control,
but also for overall hypoglycemia management in patients with diabetes
[6,14].
As a result of multiple iterations, factor analysis resulted in a 12point questionnaire with higher scores (ranging from 1 to 5) reflecting
less clinical inertia for hypoglycemia.
The multiple regression analysis showed that, for this population,
there was no statistically significant association between the Clin
Inert_InHypoDM scale score and FPs’ characteristics, including sex, years
in practice, average number of DM patients seen per week, practice type,
practice location, certified diabetes educator and personal diagnosis of
diabetes.
Therefore, based on adjusted analyses, clinical inertia did not seem
to be related to characteristics that are not amenable to change, such as
gender or years in practice. Nor was it influenced by the location and
type of clinical practice. Counterintuitively, clinical inertia had no
relation to the physician’s experience with DM management measured
in the average number of DM patients seen in a regular work week or by
being a certified diabetes educator. These results imply that all FPs
managing DM patients at risk for hypoglycemia should be watchful for
attitudes associated with clinical inertia.
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improve outcomes for DM patients.
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This study was the first of its kind to measure clinical inertia for
hypoglycemia management in primary care. As such, it serves as a
foundation for future research to test, validate and build upon. The
creation of the ClinInert_InHypoDM scale for hypoglycemia management
is the first step in the development and validation of a scale to measure
an important and largely under-studied clinical issue. By using this scale,
we may gain an understanding about the factors that influence clinical
inertia behavior in FPs in the management of hypoglycemia. It will be
useful to further validate the scale in the future in other family physician
populations.
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Supplementary material related to this article can be found, in the
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